Stem cell researcher Konrad Hochedlinger of Harvard University, who last year reported using
a safer type of virus to generate iPS cells agrees that «these papers are an important advance.»
«As it recognises all four dengue
virus types, it provides the basis
of a
safe and broad - spectrum anti-dengue therapy as well as informing the next generation
of dengue vaccines,» he said.